145 related articles for article (PubMed ID: 10865036)
1. Molecular genetics of thyroid tumors and surgical decision-making.
Learoyd DL; Messina M; Zedenius J; Robinson BG
World J Surg; 2000 Aug; 24(8):923-33. PubMed ID: 10865036
[TBL] [Abstract][Full Text] [Related]
2. [Thyroid carcinoma: genetics, diagnosis, clinical features, and surgical treatment].
Takami H; Ikeda Y; Tajima G; Kan S; Kameyama K
Nihon Geka Gakkai Zasshi; 2002 Jun; 103(6):492-4. PubMed ID: 12094702
[TBL] [Abstract][Full Text] [Related]
3. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors.
Dahia PL; Marsh DJ; Zheng Z; Zedenius J; Komminoth P; Frisk T; Wallin G; Parsons R; Longy M; Larsson C; Eng C
Cancer Res; 1997 Nov; 57(21):4710-3. PubMed ID: 9354427
[TBL] [Abstract][Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
[TBL] [Abstract][Full Text] [Related]
6. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
[TBL] [Abstract][Full Text] [Related]
7. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
[TBL] [Abstract][Full Text] [Related]
9. Oncogenes and thyroid cancer.
Vecchio G; Santoro M
Clin Chem Lab Med; 2000 Feb; 38(2):113-6. PubMed ID: 10834397
[TBL] [Abstract][Full Text] [Related]
10. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia.
Zou M; Shi Y; Farid NR
Cancer; 1994 Jan; 73(1):176-80. PubMed ID: 8275421
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
[TBL] [Abstract][Full Text] [Related]
12. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.
Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F
J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Romei C; Ciampi R; Elisei R
Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437
[TBL] [Abstract][Full Text] [Related]
15. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
16. Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer.
Fugazzola L; Cerutti N; Mannavola D; Ghilardi G; Alberti L; Romoli R; Beck-Peccoz P
Clin Endocrinol (Oxf); 2002 Jan; 56(1):53-63. PubMed ID: 11849247
[TBL] [Abstract][Full Text] [Related]
17. [Genetic causes of the thyroid carcinomas].
Jindrichová S; Vlcek P; Bendlová B
Cas Lek Cesk; 2004; 143(10):664-8. PubMed ID: 15584614
[TBL] [Abstract][Full Text] [Related]
18. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma.
Jhiang SM; Fithian L; Weghorst CM; Clark OH; Falko JM; O'Dorisio TM; Mazzaferri EL
Thyroid; 1996 Apr; 6(2):115-21. PubMed ID: 8733882
[TBL] [Abstract][Full Text] [Related]
19. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
20. Molecular biology of thyroid neoplasms.
Satta MA; Nanni S; Della Casa S; Pontecorvi A
Rays; 2000; 25(2):151-61. PubMed ID: 11370534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]